课题基金 / 基金详情

项目摘要

项目成果

JON Owen NAGY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This Phase I SBIR project seeks to develop specialized protein-polymer nanoparticles that are engineered to a therapeutic drug to counter the ill effects following exposure to organophosphate (OP) insecticides. The concept for these nanoparticles is based on 'customized, triggered-release' in which the membrane of a polymerized liposome nanoparticle (PLN) displays functional acetylcholinesterase, the primary target for OPs, while a therapeutic cargo is encapsulated (e.g., oxime). During an OP exposure, the AChE is inhibited (the same as exogenous ChE) to cause protein changes that later the polymeric nanoparticle membrane allowing the oxime cargo (various mechanisms possible) to be released and immediately available to restore exogenous ChE. Because the PLNs are customized and specific to OPs, PLN-AChE nanoparticles will not produce unwanted, high concentrations of the therapeutic agents in the body without OP exposure. In this application, we will develop and subsequently show that AChE-PLNs can be generated with functional enzyme and are selectively inhibited by organophosphates (OP). We will further demonstrate that small molecule cargo can be loaded and stored in functional AChE-PLNs that reaction with OPs releases the entrapped cargo. We will produce ¿ 25 mg each of three functional, intact ChE-PLNs in readiness for the Phase II portion of this R&D project. PUBLIC HEALTH RELEVANCE: Citizens can be exposed to organophosphate (OP) insecticides via domestic application, aerial spraying, crops, as a pediculicide, and through the food chain. Accidental exposure to OP- containing pesticides can cause many tiers of toxicity, injury or be fatal to humans. For decades, only high-level exposures to OPs receive medical attention because low, chronic exposures have gone unchecked largely because they can asymptomatic, usually manifesting illnesses through accumulated exposures. If therapeutic measures could be available through a preventative process and highly specific toward OP exposures, a reduction in short- and long- term ill health effects could be expected.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
  • 批准号:
    10706449
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2023
  • 负责人:
    JON Owen NAGY
  • 依托单位:
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy
  • 批准号:
    9903613
  • 项目类别:
  • 资助金额:
    $101.93万
  • 财政年份:
    2018
  • 负责人:
    JON Owen NAGY
  • 依托单位:
NV103: Antibody Conjugated Nanoparticle for Ewing Sarcoma Targeted Therapy
  • 批准号:
    9919322
  • 项目类别:
  • 资助金额:
    $89.28万
  • 财政年份:
    2018
  • 负责人:
    JON Owen NAGY
  • 依托单位:
Development of a selective biosensor for detecting organophosphate pesticide expo
  • 批准号:
    7363825
  • 项目类别:
  • 资助金额:
    $29.87万
  • 财政年份:
    2007
  • 负责人:
    JON Owen NAGY
  • 依托单位:
国内基金
海外基金
转录因子BMAL1调控AChE在昼夜节律紊乱致认知损害中的作用及分子机制
基于无机基质固定碳点光学探针研究有机磷农药暴露AChE响应的活体测量
  • 批准号:
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2024
  • 负责人:
    冯锋
  • 依托单位:
基于AChE/NLRP3 靶点研究垂穗石松中抗AD新型黄酮苷 吐星酸酯类成分的发现及作用机制研究
基于GSK-3β/AChE双重抑制的抗AD杂交分子的设计、合成及作用机制研究
  • 批准号:
    22367005
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    32万元
  • 批准年份:
    2023
  • 负责人:
    董永喜
  • 依托单位: